Infants and children aged <2 years are recommended to receive MenB vaccine
All infants and children aged <2 years are recommended to receive the MenB vaccine. The MenB vaccine used in infants and children aged <2 years is Bexsero, which is currently the only MenB vaccine registered and available in Australia. The number of doses required depends on the age of the child when they start the vaccine course.
A booster dose of MenB vaccine (i.e. an extra dose beyond those recommended for primary vaccination, see Table. Recommendations for immunisation of infants and children aged <2 years using meningococcal B vaccine) is not recommended in children at standard background risk of invasive meningococcal disease (see Variations from product information).
Medical conditions are specified in List. Specified medical conditions associated with increased risk of invasive meningococcal disease.
| Age at start of vaccine course | MenB vaccine brand | Dose requirements for healthy people (without any medical conditions associated with increased risk of invasive meningococcal disease) |
|---|---|---|
| 6 weeks to 11 months | Bexsero | 3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age or 8 weeks after 2nd dose, whichever is later) |
| 12–23 months | Bexsero | 2 doses (8 weeks between doses) |